INOVIO, a biotech company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced it will present at two upcoming scientific conferences in November 2026. The presentations will cover next-generation DNA medicine for rare disease protein replacement and a new therapy for Hemophilia A. These events highlight INOVIO's ongoing innovation in DNA-based treatments, potentially advancing options for patients with rare and genetic diseases. Abstracts and presentations will be available on INOVIO's events page after the conferences.
As of Nov 03, 2026 04:11 WIB, INOVIO (INO) is trading on Pluang at USD 1.86, showing a remarkable 208.76% increase in one day. The stock has a market cap of $62.04 million and an enterprise value of $33.37 million. Despite the strong price surge, Pluang order activity is fairly balanced with 51% selling and 49% buying interest.
